Dossier assessment
Baricitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Baricitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Baricitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with moderate to severe atopic dermatitis who are candidates for systemic therapy
Added benefit not proven for either of both research questions (longterm/continued systemic therapy indicated or not indicated)
Project details
- Project no.
- A20-95
- Commission
- Commission awarded on 16.11.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Baricitinib (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Baricitinib (juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Baricitinib (atopic dermatitis, 2 to 17 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Baricitinib (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed